EMPULSE trial shows treatment of patients acutely hospitalized for heart failure with empagliflozin led to a rapid incremental increase in patient well-being, compared with control patients who received placebo.
The Blue Valley Post talked to Dr. Chris Bowser about trends local emergency departments see over the warmer months and how to avoid becoming part of the trend.
A new study by Dr. Kosiborod and colleagues found clinical benefits in treatment with empagliflozin for patients hospitalized with acute heart failure.
A secondary analysis of the EMPULSE trial provides more context to the quality-of-life benefits of the early initiation of empagliflozin in patients hospitalized with acute decompensated heart failure.
